360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Solvay Pharmaceuticals

Type: Company

Name: Solvay Pharmaceuticals (Solvay Pharma India Limited)

Web Address: http://www.solvay-pharma.se

Fact Sheet: Fact Sheet for Solvay Pharma India Limited

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Abbott India 1QCY2013 performance highlights and results update

For 1QCY2013, Abbott India (AIL) reported an 11.6% yoy growth in top-line at Rs.420cr, although 3.2% lower than our estimate of Rs.433cr. The EBITDA margin expanded by 313bp yoy, primarily due to lower raw material prices and lower other expenses. However, ... [Published Stock Markets Review - May 03 2013]

Entities: Abbott India Ltd, EBITDA, CAGR, Raw Material, Synergism

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Lipitor

Caplan: It's time to end pay-for-delay

Whether you are young or old, man or woman, very healthy or quite sick, it is almost a certainty that you are going to use a prescription drug in the next year or two. These medicines are crucial for preventing diseases and treating all sorts of ailments ... [Published WDSU New Orleans - Apr 25 2013]

Entities: Drugs, Lipitor, Testosterone

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Medtronic Inc

Reply – Weighing in on Congestion

Muthiah Vaduganathan, MD, MPH; Gregg C. Fonarow, MD, FACC; Robert O. Bonow, MD, MS, MACC; Mihai Gheorghiade, MD, FACCDisclosures: Dr. Vaduganathan: No relevant relationships to disclose.; Dr. Fonarow: Research support - Agency for Healthcare Research ... [Published Journal of the American College of Cardiology - Apr 25 2013]

Entities: Medtronic Inc, Novartis AG, Gregg C Fonarow

First reported Apr 23 2013 - Updated Apr 23 2013 - 1 reports

Actavis

Future of pay-for-delay in hands of SCOTUS

Last month, the Supreme Court heard Federal Trade Commission v. Actavis, which could impact the future of the generic drug industry at a time when 80% of all prescriptions dispensed in the United States are generic.The case involves a deal between Solvay ... [Published Drug Store News - Apr 23 2013]

Entities: Generic Drug, Drugs, Actavis, Patent, Watson Pharmaceuticals Inc

First reported Apr 16 2013 - Updated Apr 16 2013 - 1 reports

Aeterna Zentaris Inc names David A Dodd president and CEO

Oncology company Aeterna Zentaris Inc (NasdaqGM:AEZS) (TSX:AEZ) revealed on Monday the appointment of David A Dodd as its president, chief executive officer and board director, replacing Dr Juergen Engel. Currently, Dodd serves as chair and board member ... [Published Individual.com - Apr 16 2013]

Entities: AEterna Zentaris Inc, Stem Cell Sciences PLC, Serologicals Corporation, GeoVax

First reported Apr 15 2013 - Updated Apr 15 2013 - 1 reports

Motley Fool

Aeterna Zentaris Names New CEO

Filed under: InvestingAeterna Zentaris has made a significant change in its executive suite and boardroom. David Dodd is now the company's chief executive and a member of its board of directors. He succeeds Juergen Engel. The firm did not provide the ... [Published Daily Finance - Apr 15 2013]

Entities: AEterna Zentaris Inc, David Dodd, Motley Fool

First reported Apr 12 2013 - Updated Apr 12 2013 - 1 reports

Janssen Pharmaceutica

Country Report: Belgium

Project Director: Béatrice ColletProject Coordinator: Aleksandra KlassenEditorial Coordinator: Roslan KhasawnehProject Publisher: Mary Carmen Luna Matuk & Ines Nandin For exclusive interviews and more info, please log onto or write to contact@focusre ... [Published Pharmaceutical Executive - Apr 12 2013]

Entities: Belgium, Life Science, Beerse (Belgium), Solvay Pharmaceuticals, Janssen Pharmaceutica

First reported Mar 25 2013 - Updated Mar 25 2013 - 1 reports

Supreme Court Hears Pay-To-Delay Arguments Today

After months of anticipation, the US Supreme Court today will review the so-called pay-to-delay agreemeents in which a brand-name drugmaker agrees to pay a settlement to a generic rival in exchange for ending patent litigation and launching a copycat ... [Published Pharmalot - Mar 25 2013]

Entities: Supreme Court, AndroGel, Solvay SA

First reported Mar 25 2013 - Updated Mar 25 2013 - 1 reports

‘Pay-to-delay’ pharmaceutical deals smack of illegal collusion - WaPo

IN 2006 Solvay Pharmaceuticals, the maker of the testosterone-therapy drug AndroGel, settled a dispute with a group of generic pharmaceutical companies, agreeing to allow would-be competitors into the market in 2015, five years before the AndroGel patent ... [Published PharmaGossip - Mar 25 2013]

Entities: Collusion, Patent, Illegal, AndroGel

First reported Mar 21 2013 - Updated Mar 22 2013 - 1 reports

U.S. Supreme Court Hearings on Drug Company Settlements

Reuters reported the U.S. Supreme Court is beginning hearings on arguments during the last week of March 2013 in a case challenging payments provided by brand-name drug manufacturers to generic companies to settle patent lawsuits. The case ... [Published JD Journal.com - Mar 21 2013]

Entities: US Supreme Court, Solvay SA, Drugs, Patent

First reported Mar 11 2013 - Updated Mar 11 2013 - 1 reports

Sometimes It’s Anything But Discovery

Maybe it’s the word. It sounds so positive and promising: “Discovery.” Discovery leads to good and helpful things: “Einstein discovered relativity.” “Ben Franklin discovered electricity” (well, not really, but he was big in electricity). When we discover ... [Published Drug and Device Law - Mar 11 2013]

Entities: Corroboration, Subpoena, Relativity, Allegation

First reported Feb 01 2013 - Updated Feb 01 2013 - 1 reports

FTC Chairman Jon Leibowitz To Step Down In February

* Led probe into Google that ended with mild reprimand * Passionate about drugmaker "pay for delay" cases* Two current commissioners among those seen in runningBy Diane BartzWASHINGTON, Jan 31 (Reuters) - The chairman of the Federal Trade Commission, ... [Published The Huffington Post | Full News Feed - Feb 01 2013]

Entities: Jon Leibowitz, Google Inc, Julie Brill, Solvay Pharmaceuticals, AndroGel

Quotes

Serono "), in all jurisdictions. The transactions are expected to be"

(PR) Aeterna Zentaris Reports First Quarter 2013 Financial and Operating Results [Published Scottrade - May 07 2013]

Best of all? It's easy. "Low T Center is set up so men can walk in, take a simple blood test, and know within 30 minutes whether or not they are a candidate for testosterone replacement therapy, or TRT. Men who qualify get their first injection on the spot, and will continue to come in three times per month to receive a quick testosterone injection."

The Testosterone Trap [Published PharmaGossip - May 02 2013]

More Content

sort by: Date \| Relevance
(PR) Aeterna Zentaris Reports First Quarter 201... [Published Scottrade - May 07 2013]
Now Available: Global and China Tire Mold Indus... [Published SBWire - May 07 2013]
Abbott India 1QCY2013 performance highlights an... [Published Stock Markets Review - May 03 2013]
The Testosterone Trap [Published PharmaGossip - May 02 2013]
Pharmaceutical supply chain - Indian perspective [Published Express Pharma - May 01 2013]
David A. Dodd appointed president and CEO of Ae... [Published Center Watch - Apr 27 2013]
Opinion: Why the Supreme Court should end pay-f... [Published CNN - Apr 25 2013]
Caplan: It's time to end pay-for-delay [Published WDSU New Orleans - Apr 25 2013]
Reply – Weighing in on Congestion [Published Journal of the American College of Cardiology - Apr 25 2013]
Future of pay-for-delay in hands of SCOTUS [Published Drug Store News - Apr 23 2013]
Aeterna Zentaris appoints new president and CEO [Published Individual.com - Apr 22 2013]
Research and Markets: Seasonal Influenza Vaccin... [Published Business Wire - Apr 18 2013]
Seasonal Influenza Vaccine Market in Asia-Pacif... [Published Individual.com - Apr 18 2013]
Aeterna Zentaris Inc names David A Dodd preside... [Published Individual.com - Apr 16 2013]
Aeterna Zentaris Names New CEO [Published Daily Finance - Apr 15 2013]
David A. Dodd Appointed CEO of AEterna Zentaris... [Published FierceBiotech - Apr 15 2013]
David A. Dodd Appointed President & Chief Execu... [Published Equities.com - Apr 15 2013]
April 15, 2013 David A. Dodd Appointed Presiden... [Published Noodls - Apr 15 2013]
AETERNA ZENTARIS INC.: April 15, 2013 David A. ... [Published 4 Traders - Apr 15 2013]
David A. Dodd Appointed President & Chief Execu... [Published Canada NewsWire - Apr 15 2013]
Country Report: Belgium [Published Pharmaceutical Executive - Apr 12 2013]
Jan and Karin Heitmann Join RE/MAX Alliance Group [Published PR.com Press Releases - Apr 07 2013]
Supreme Court Hears Pay-To-Delay Arguments Today [Published Pharmalot - Mar 25 2013]
‘Pay-to-delay’ pharmaceutical deals smack of il... [Published PharmaGossip - Mar 25 2013]
The Big Day Approaches: Supreme Court to Hear O... [Published FDA Law Blog - Mar 24 2013]
Argument preview: Is “pay for delay” of drugs i... [Published SCOTUSblog - Mar 22 2013]
U.S. Supreme Court Hearings on Drug Company Set... [Published JD Journal.com - Mar 21 2013]
Sometimes It’s Anything But Discovery [Published Drug and Device Law - Mar 11 2013]
Research and Markets: Global Endocrinology Drug... [Published Yahoo! Finance - Feb 19 2013]
Research and Markets: Global Endocrinology Drug... [Published Business Wire Health News - Feb 19 2013]

Blogs

sort by: Date \| Relevance
The Testosterone Trap [Published PharmaGossip - May 02 2013] Should the Modern Man Be Taking Testosterone?Is It Low T? .comBy now you've likely seen the commercials. Fit-looking middle-age men telling you how they put on weight, had less energy, and were no longer the sexual tigers they were in their twenties -- ...
Supreme Court Hears Pay-To-Delay Arguments Today [Published Pharmalot - Mar 25 2013] After months of anticipation, the US Supreme Court today will review the so-called pay-to-delay agreemeents in which a brand-name drugmaker agrees to pay a settlement to a generic rival in exchange for ending patent litigation and launching a copycat ...
‘Pay-to-delay’ pharmaceutical deals smack of il... [Published PharmaGossip - Mar 25 2013] IN 2006 Solvay Pharmaceuticals, the maker of the testosterone-therapy drug AndroGel, settled a dispute with a group of generic pharmaceutical companies, agreeing to allow would-be competitors into the market in 2015, five years before the AndroGel patent ...
The Big Day Approaches: Supreme Court to Hear O... [Published FDA Law Blog - Mar 24 2013] By Kurt R. Karst –Excitement is running high in the pharmacetical world with just hours to go before the U.S. Supreme Court hears oral argument on Monday, March 25, 2013 in Federal Trade Commission v. Actavis (Docket No. 12-416) concerning whether drug ...
Argument preview: Is “pay for delay” of drugs i... [Published SCOTUSblog - Mar 22 2013] At 11 a.m. Monday, the Supreme Court will hold one hour of oral argument on the legality, under antitrust laws, of payments by the maker of a brand-name drug to the maker of a generic substitute to keep the generic off the market temporarily. In the ...

Press Releases

sort by: Date \| Relevance
Research and Markets: Seasonal Influenza Vaccin... [Published Business Wire - Apr 18 2013]
Jan and Karin Heitmann Join RE/MAX Alliance Group [Published PR.com Press Releases - Apr 07 2013]
Research and Markets: Global Endocrinology Drug... [Published Business Wire Health News - Feb 19 2013]